These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 22301884)
1. Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteins. Furtado JD; Wedel MK; Sacks FM J Lipid Res; 2012 Apr; 53(4):784-91. PubMed ID: 22301884 [TBL] [Abstract][Full Text] [Related]
2. Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia. Campos H; Perlov D; Khoo C; Sacks FM J Lipid Res; 2001 Aug; 42(8):1239-49. PubMed ID: 11483625 [TBL] [Abstract][Full Text] [Related]
3. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058 [TBL] [Abstract][Full Text] [Related]
4. In-vivo metabolism of VLDL-apolipoprotein-B, -CIII and -E in normolipidemic subjects. Dinkel RE; Barrett PH; Demant T; Parhofer KG Nutr Metab Cardiovasc Dis; 2006 Apr; 16(3):215-21. PubMed ID: 16580589 [TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Zheng C; Khoo C; Furtado J; Sacks FM Circulation; 2010 Apr; 121(15):1722-34. PubMed ID: 20368524 [TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein E in VLDL and LDL with apolipoprotein C-III is associated with a lower risk of coronary heart disease. Mendivil CO; Rimm EB; Furtado J; Sacks FM J Am Heart Assoc; 2013 May; 2(3):e000130. PubMed ID: 23672999 [TBL] [Abstract][Full Text] [Related]
7. Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Témoins sur 'Infarctus du Myocarde. Luc G; Fievet C; Arveiler D; Evans AE; Bard JM; Cambien F; Fruchart JC; Ducimetiere P J Lipid Res; 1996 Mar; 37(3):508-17. PubMed ID: 8728314 [TBL] [Abstract][Full Text] [Related]
8. Effects of estrogenic oral contraceptives on the lipoprotein B particle system defined by apolipoproteins E and C-III content. Khoo C; Campos H; Judge H; Sacks FM J Lipid Res; 1999 Feb; 40(2):202-12. PubMed ID: 9925648 [TBL] [Abstract][Full Text] [Related]
9. Enrichment of Triglyceride-Rich Lipoproteins with Apolipoprotein C-I Is Positively Associated with Their Delayed Plasma Clearance Independently of Other Transferable Apolipoproteins in Postmenopausal Overweight and Obese Women. Wassef H; Bissonnette S; Dufour R; Davignon J; Faraj M J Nutr; 2017 May; 147(5):754-762. PubMed ID: 28356429 [No Abstract] [Full Text] [Related]
15. The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia. Sacks FM Curr Opin Lipidol; 2015 Feb; 26(1):56-63. PubMed ID: 25551803 [TBL] [Abstract][Full Text] [Related]
16. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins. Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484 [TBL] [Abstract][Full Text] [Related]
17. Common APOC3 variants are associated with circulating ApoC-III and VLDL cholesterol but not with total apolipoprotein B and coronary artery disease. Silbernagel G; Scharnagl H; Kleber ME; Hoffmann MM; Delgado G; Stojakovic T; Gary T; Zeng L; Ritsch A; Zewinger S; Speer T; Schunkert H; Landmesser U; März W; Grammer TB Atherosclerosis; 2020 Oct; 311():84-90. PubMed ID: 32949947 [TBL] [Abstract][Full Text] [Related]
18. Fate of apolipoproteins C-1, C-iii, and E during lipolysis of human very low density lipoproteins in vitro. Tam SP; Dory L; Rubinstein D J Lipid Res; 1981 May; 22(4):641-51. PubMed ID: 7276737 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia. Reeskamp LF; Kastelein JJP; Moriarty PM; Duell PB; Catapano AL; Santos RD; Ballantyne CM Atherosclerosis; 2019 Jan; 280():109-117. PubMed ID: 30500603 [TBL] [Abstract][Full Text] [Related]
20. [THE LIPOLYSIS IN PHYLOGENETICALLY EARLY LIPOPROTEINS OF LOW DENSITY AND MORE LATER LIPOPROTEINS OF VERY LOW DENSITY: FUNCTION AND DIAGNOSTIC VALUE OF APOE AND APOC-III]. Rozhkova TA; Titov VN; Amelyushkina VA; Kaba SI; Kukhartchuk VV Klin Lab Diagn; 2015 Dec; 60(12):4-14. PubMed ID: 27032246 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]